Drug intelligence / Profile preview

177Lu-Lumi4-anti-HER2 monoclonal antibody

Development stage: Preclinical
Lead developer: Lumiphore
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177Lu-Lumi4-anti-HER2 monoclonal antibody is a preclinical-stage radiopharmaceutical developed by Lumiphore for the treatment of HER2-expressing solid tumors. It consists of an anti-HER2 monoclonal antibody conjugated to the beta-emitting radioisotope lutetium-177 (177Lu) using Lumiphore's proprietary Lumi4 macrocyclic bifunctional chelate (mBFC) technology. The antibody component targets the Human Epidermal Growth Factor Receptor 2 (HER2), delivering targeted radiotherapy directly to cancer cells. This approach is being explored for various HER2-positive malignancies, including breast, gastric, ovarian, lung, and endometrial cancers, as well as salivary duct carcinomas.

Brand names: Lumi4-Anti-HER2Lumi-4-Anti-HER2Lumi 4-Anti-HER2
Other names: 177Lu-Lumi4-Anti-HER2-mAbLumi4-Anti-HER2Lumi-4-Anti-HER2Lumi 4-Anti-HER2

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on 177Lu-Lumi4-anti-HER2 monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-Lumi4-anti-HER2 monoclonal antibody.